Pharmacy

Your Article Summary

See Latest Articles

Treating Multidrug-Resistant TB
JAMA, 07/16/09

Stephenson J - A new drug with a novel mechanism of action against tuberculosis infection shows promise for treating multidrug-resistant tuberculosis (MDR-TB). The drug, TMC207, is a diarylquinoline that inhibits the enzyme adenosine triphosphate (ATP) synthase, disrupting the production of ATP, the molecule that serves as the energy currency of cells.

Today in Antimicrobials...keeping you current

Receive free subspecialty "5-minute updates" via email

Temporal Reduction of HIV Type 1 Viral Load in Breast Milk by Single-Dose Nevirapine during Prevention of MTCT
AIDS Research and Human Retroviruses, 12/18/09

Update on the efficacy, effectiveness and safety of artemether–lumefantrine combination therapy for treatment of uncomplicated malaria
Therapeutics and Clinical Risk Management, 12/18/09

Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action
Clinical Pharmacokinetics, 12/18/09

 See all of Antimicrobials

Today in Drug Resistance...keeping you current

Receive free subspecialty "5-minute updates" via email

Selection and counterselection of the adefovir resistance mutation rtI233V during antiviral therapy
Journal of Clinical Microbiology, 12/18/09

Comparative proteomic profiling identified sorcin being associated with gemcitabine resistance in non-small cell lung cancer
Medical Oncology, 12/18/09

Epidemiology and Evolution of Invasive Pneumococcal Disease Caused by Multidrug Resistant Serotypes of 19A in the 8 Years After Implementation of Pneumococcal Conjugate Vaccine Immunization in Dallas, Texas
The Pediatric Infectious Disease Journal, 12/17/09

 See all of Drug Resistance